ReviewCurrent treatment options in neurology2018
Pediatric Neuromyelitis Optica Spectrum Disorders.
Review in Current treatment options in neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 39 citations in OpenAlex.
- Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum Disorder.Pediatric neurology · 2024Article
- Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents.Arquivos de neuro-psiquiatria · 2023Review
- Risk Factors and Nomogram for Predicting Relapse Risk in Pediatric Neuromyelitis Optica Spectrum Disorders.Frontiers in immunology · 2022Article
- Identification of the clinical and neuroimaging characteristics in children with neuromyelitis optica spectrum disorders: a case series.Translational pediatrics · 2021Article
- Assessment and Management of Acute Disseminated Encephalomyelitis (ADEM) in the Pediatric Patient.Paediatric drugs · 2021Review
- [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification].Der Nervenarzt · 2021Review
- Can Immune Tolerance Be Re-established in Neuromyelitis Optica?Frontiers in neurology · 2021Review
- Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis.Frontiers in pediatrics · 2020Review
- Epidemiology of Pediatric NMOSD in Germany and Austria.Frontiers in neurology · 2020Article
- Acute Transverse and Flaccid Myelitis in Children.Current treatment options in neurology · 2019Review
- Update on pediatric optic neuritis.Current opinion in ophthalmology · 2019Review
- 14th EUNOS Congress: PORTO, PORTUGAL, 16-19 JUNE 2019.Neuro-ophthalmology (Aeolus Press) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewNeuromyelitis optica spectrum disorders (NMOSDs) are a group of inflammatory and demyelinating disorders of the central nervous system that can occur in children and adults. The classic presentation of NMOSD is characterized by optic neuritis and transverse myelitis, but other presentations are also recognized, expanding the disease as NMO spectrum disorders. The purpose of this review is to discuss the clinical features, along with management and treatment options, including potential future therapeutic options, in pediatric NMOSD. RECENT
findingsThe aquaporin-4 antibody (AQP4 ab) is specific for NMOSD; however, recently another antibody, the myelin oligodendrocyte glycoprotein (MOG ab) has been found in a subset of AQP4 ab-negative patients including in children. Most treatment studies are reported in adults, but retrospective studies on efficacy and safety of mycophenolate mofetil, azathioprine, and rituximab in pediatric NMOSD are available. While some pediatric NMOSD-specific treatment studies are available, more research is needed in the mechanisms of early onset and specific treatment options in children, including whether different treatment considerations are needed for AQP4 ab as opposed to MOG ab-positive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.